HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that data about the progress of Nymox’s drug development for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH), were presented this morning at the 84th Annual Meeting of the Western Section of the American Urological Association being held in Monterey, CA. Barrett Cowan, MD, FACS, of Denver made the podium presentation. Dr. Cowan is an independent clinical investigator who has participated in the NX-1207 clinical trials for the past 4 years as well as follow-up studies of the drug. NX-1207 is now in Phase 3 development.
